Metabolomics Services to Take You Beyond the Genome

While the vast majority of biomarker discovery for drug development has focused on genomics, more than 80% of disease risk is non-genetic. Small molecule biomarkers read out these exogenous influences and how they impact health and disease over time. The challenge is that this vast molecular landscape has been difficult and slow to map given traditional bioanalytical constraints… until now.

Sapient’s discovery metabolomics services, backed by next-gen mass spectrometry, finally provide a way to broadly and rapidly profile the tens of thousands of metabolites and lipids circulating in humans, opening an entirely new expanse from which robust biomarkers for drug development can be identified.